Ron Levy, MD, professor of Medicine at Stanford, recounts his experiences moving his discovery from the lab to the clinical setting and discusses the future of this cancer treatment. Wendy Harpham, a participant in the early clinical trials of Rituxan, the first FDA-approved monoclonal antibody for cancer treatment that Levy developed, provides a patient's perspective.
Stanford University School of Medicine:
MEDCAST puts you in the front row at some of the leading-edge lectures at the School of Medicine. Tune in to watch Stanford faculty and other renown experts discuss the latest advances in biomedical research, patient care and other health-related fields.
More Information: http://med.stanford.edu/medcast/